8 completed, 8 unknown, 4 not yet recruiting, 2 recruiting. 22 Phase 2, 9 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 8, Unknown 8, Not yet recruiting 4, Recruiting 2 |
| Phase 1 | 9 | Unknown 4, Not yet recruiting 2, Recruiting 2, Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety | Phase 2 | Not yet recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 60 | 2028-05-25 | 2025-11-25 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy - Efficacy | Phase 1 / Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 150 | 2024-10-01 | 2024-10-09 |
| Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency Niraparib - Efficacy | Phase 2 | Not yet recruiting | Korea University Anam Hospital | 33 | 2024-02-27 | 2024-02-01 |
| Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Efficacy | Phase 2 | Completed | Sun Yat-sen University | 170 | 2024-02-15 | 2026-08-03 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| A Study of GC101 TIL in Advanced Melanoma (BZ) GC101 TIL - Tumor Infiltrating Lymphocytes, Safety | Phase 1 / Phase 2 | Completed | Shanghai Juncell Therapeutics | 18 | 2023-11-08 | 2025-12-23 |
| Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer Tirolizumab+SOX/XELOX, SOX/XELOX - Locally Advanced Gastric Carcinoma, HER2 Negative | Phase 2 | Unknown | Lin Chen | 80 | 2023-10-01 | 2024-02-29 |
| A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab Oral sotorasib + IV Panitumumab - Efficacy | Phase 2 | Unknown | Korea University Anam Hospital | 24 | 2023-07-03 | 2023-08-15 |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors Cadonilimab, Stereotactic body radiotherapy - Advanced Solid Tumor, Stereotactic Body Radiotherapy | Phase 1 / Phase 2 | Unknown | Peking University Third Hospital | 60 | 2023-06-21 | 2023-06-23 |
| Is Local Injection of Mesenchymal Stem Cells After Endoscopic Dilation Safe and Does it Improve the Outcome of Intestinal Stricture in Patients With Crohn's Disease? Mesenchymal Stem Cells, Comparative placebo - Safety Issues, Efficacy | Phase 2 | Unknown | Centre Hospitalier Universitaire de Liege | 50 | 2023-06-06 | 2024-03-19 |
| A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB Hepenofovir Fumarate Tablets - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 48 | 2022-11-10 | 2023-11-08 |
| PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer PD-L1 inhibitor - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2022-04-01 | 2022-04-13 |
| Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma Sintilimab 200mg+MB07133 600mg - Safety Issues, Efficacy | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 39 | 2022-01-18 | 2023-11-21 |
| Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients Advixa (Adalimumab) - Pharmacokinetics, Safety | Phase 2 / Phase 3 | Unknown | Institute for Developing Science and Health Initiatives, Bangladesh | 200 | 2021-06-02 | 2022-07-07 |
| A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes Placebo, XEN-D0501 - Efficacy, Safety | Phase 2 | Completed | Pila Pharma | 54 | 2019-02-25 | 2022-04-29 |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer Bevacizumab - Metastatic Triple Negative Breast Cancer, Safety Issues | Phase 2 | Completed | Assiut University | 54 | 2018-07-01 | 2021-03-09 |
| A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma 800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily - Asthma, Efficacy | Phase 2 | Completed | AstraZeneca | 54 | 2015-06-25 | 2018-02-15 |
| Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia iloperidone, Risperidone - Schizophrenia, Iloperidone | Phase 2 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 260 | 2012-06-01 | 2013-11-19 |
Showing 20 of 22. Sign in to see all of them.
Arthritis, Rheumatoid (1) · Asthma (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Diabetes Mellitus, Type 2 (1) · Drug-Related Side Effects and Adverse Reactions (1) · Esophageal Squamous Cell Carcinoma (1) · Melanoma (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Schizophrenia (1) · Spinal Cord Injuries (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Skin and Connective Tissue Diseases (3) · Immune System Diseases (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Respiratory Tract Diseases (2) · Skin Diseases (2) · Arthritis (1) · Autoimmune Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1)
Cisplatin (2) · Gemcitabine (2) · 4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (1) · Adalimumab (1) · Albuterol (1) · Bevacizumab (1) · Capecitabine (1) · Dexamethasone (1) · Folic Acid (1) · Immune Checkpoint Inhibitors (1) · Injections (1) · Injections, Subcutaneous (1) · Oxaliplatin (1) · Panitumumab (1) · Radiosurgery (1)
Sichuan Huiyu Pharmaceutical Co., Ltd (3) · Korea University Anam Hospital (2) · Sun Yat-sen University (2) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Assiut University (1) · AstraZeneca (1) · Centre Hospitalier Universitaire de Liege (1) · Hunan Province Tumor Hospital (1) · Institute for Developing Science and Health Initiatives, Bangladesh (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Lin Chen (1) · Peking University Third Hospital (1) · Pila Pharma (1) · Shanghai Juncell Therapeutics (1) · Soonchunhyang University Hospital (1)
China (11) · South Korea (2) · Bangladesh (1) · Belgium (1) · Bulgaria (1) · Egypt (1) · Germany (1) · Lithuania (1)
Andrea Ludwig-Sengpiel, Dr. (1) · Anne-Marie Kirsten, Dr. (1) · Anneliese Linnhoff, Dr. med. (1) · Christine Grigat, Dr. (1) · Dae Sik Hong, professor (1) · Dirk Skowasch, Prof. (1) · Dorte X Gram, PhD (1) · Hongqing Zhuang, M.D. (1) · Hui Liu, Professor (1) · Jun Guo (1) · Jutta Beier, Dr. med. (1) · Li Zhang, MD (1) · Limin Rong, prof and M.D (1) · Margret Jandl, Dr. (1)
PMID 21383283, PMID 22415477, PMID 23075681, PMID 27501767, PMID 30777086, PMID 33538338, PMID 34407054, PMID 40693391
2014 (1), 2018 (1)